Related content

Factors influencing warfarin dose requirements in African––Americans

By Momary Kathryn M   Shapiro Nancy L   Viana Marlos AG   Nutescu Edith A   Helgason Cathy M   Cavallari Larisa H  

Pharmacogenomics, Vol. 8, Iss. 11, 2007-11 ,pp. : 1535-1544

Future Medicine

Access to resources Recommend Favorite

Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European––Americans and African––Americans

By Limdi Nita A   Arnett Donna K   Goldstein Joyce A   Beasley T Mark   McGwin Gerald   Adler Brian K   Acton Ronald T  

Pharmacogenomics, Vol. 9, Iss. 5, 2008-05 ,pp. : 511-526

Future Medicine

Access to resources Recommend Favorite

VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African––Americans and European––Americans

By Limdi Nita A   Beasley T Mark   Crowley Michael R   Goldstein Joyce A   Rieder Mark J   Flockhart David A   Arnett Donna K   Acton Ronald T   Liu Nianjun  

Pharmacogenomics, Vol. 9, Iss. 10, 2008-10 ,pp. : 1445-1458

Future Medicine

Access to resources Recommend Favorite

CYP2C9*8 is prevalent among African––Americans: implications for pharmacogenetic dosing

By Scott Stuart A   Jaremko Malgorzata   Lubitz Steven A   Kornreich Ruth   Halperin Jonathan L   Desnick Robert J  

Pharmacogenomics, Vol. 10, Iss. 8, 2009-08 ,pp. : 1243-1255

Future Medicine

Access to resources Recommend Favorite

Predicting warfarin dosage in European–Americans and African–Americans using DNA samples linked to an electronic health record

By Ramirez Andrea H   Shi Yaping   Schildcrout Jonathan S   Delaney Jessica T   Xu Hua   Oetjens Matthew T   Zuvich Rebecca L   Basford Melissa A   Bowton Erica   Jiang Min   Speltz Peter   Zink Raquel   Cowan James   Pulley Jill M   Ritchie Marylyn D   Masys Daniel R   Roden Dan M   Crawford Dana C   Denny Joshua C  

Pharmacogenomics, Vol. 13, Iss. 4, 2012-03 ,pp. : 407-418

Future Medicine

Access to resources Recommend Favorite